HRT taskforce concluded as supply improves
Shortages earlier this year meant that thousands of women struggled to get key medication.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The hormone replacement therapy (HRT) taskforce has been wound up following an “improvement” in supply of the drugs used to alleviate menopause symptoms, the Department of Health and Social Care has said.
The head of the vaccine taskforce was reassigned to help with the HRT shortage earlier this year.
But Madelaine McTernan will now resume her normal duties after making recommendations on supply issues to government, the Department said.
I am pleased to see the situation with HRT supply is improving across the country.
DHSC said that the Menopause Taskforce, which meets every two months, will “continue to tackle issues surrounding the menopause including increasing access to treatment”.
Shortages earlier this year meant that thousands of menopausal women struggled to get key medication, which led to online swaps and medicines being offered on the black market.
A number of initiatives were launched to try to alleviate pressures on the supply chain.
This included giving pharmacists greater freedoms to supply alternatives and issuing “serious shortage protocols” on some products to limit the amount which can be dispensed to each patient to a three-month supply.
The department said that suppliers have also moved to secure additional stock and expedite deliveries of HRT products experiencing supply issues.
Officials said that there was a “substantial increase” in the supply of Oestrogel in July – one of the main products caught up in supply issues earlier this year.
Ms McTernan has recommended that dialogue continues with the industry to ensure supply and that the “serious shortage protocols” can be used where necessary.
Meanwhile, she also called for “continued assessment whether NHS formularies may be impacting access to HRT” – formularies are a list of recommended medicines.
“I am pleased to see the situation with HRT supply is improving across the country,” she said.
“I want to thank suppliers and manufacturers for their engagement and positive action to tackle this serious issue.
“I have presented my key learnings on how the department can continue to manage HRT supply and work with the industry as it continues efforts to meet rising demand.”